H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
तुलना करने के लिए मीट्रिक्स | 0ND5 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध0ND5पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 16.4x | 20.7x | −0.6x | |
PEG अनुपात | 3.80 | 0.14 | 0.00 | |
क़ीमत/बुक | 1.8x | 3.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 2.1x | 3.6x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 7.3% | 47.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 7.5% | 6.7% | अनलॉक करें |